There is a need to develop novel anticancer therapies that eliminate adverse side effects produced by current treatments. Corticotropin releasing factor (CRF), an endogenous neuroedocrine factor, which typically regulates biological and psychological indicators of stress, has recently been found to be expressed by tumor malignancies. Here, we discuss the implications of CRF as a target for antitumor therapy through regulation of tumor immune escape mechanisms.
PyterLMPinerosVGalangJA. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A. 2009;106(22):9069–9074.
2.
FitzgeraldPJ. Is norepinephrine an etiological factor in some types of cancer?Int J Cancer. 2009;124(2):257–63.
3.
JordanVC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 2009;69(4):1243–1254.
4.
FeigeJJ. Angiogenesis in adrenocortical physiology and tumor development. Ann Endocrinol (Paris). 2009;70(3):153–155.
5.
ZänkerKS. The neuro-neoplastic synapse: does it exist?Prog Exp Tumor Res. 2007;39:154–161.
6.
CroffordLJSanoHKaralisK. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest. 1992;90(6):2555–2564.
7.
CosteSCMurraySEStenzel-PooreMP. Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stress. Peptides. 2001;22(5):733–741.
8.
JessopDSHarbuzMSLightmanSL. CRH in chronic inflammatory stress. Peptides. 2001;22(5):803–7.
9.
AudhyaTJainRHollanderCS. Receptor-mediated immunomodulation by corticotropin-releasing factor. Cell Immunol. 1991;134(1):77–84.
10.
JainRZwicklerDHollanderCS. Corticotropin-releasing factor modulates the immune response to stress in the rat. Endocrinology. 1991;128(3):1329–1336.
11.
BoorseGCDenverRJ. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol. 2006;146(1):9–18.
12.
LawrenceKMLatchmanDS. The Urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem. 2006;10:1119–1126.
13.
Saito-NakayaKHasegawaRNaguraY. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol Motil. 2008;20(10):1147–1156.
14.
RalphJAZoccoDBresnihanB. A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol. 2007;170(3):1121–1133.
15.
FazalNSlominskiAChoudhryMA. Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett. 1998;435(2-3):187–190.
16.
ReubiJCWaserBValeW. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab. 2003;88(7):3312–3320.
17.
TjuvajevJKolesnikovYJoshiR. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo. 1998;12(1):1–10.
18.
GrazianiGTentoriLMuziA. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol. 2007;264(1-2):44–49.
19.
CarlsonKWNawySSWeiET. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 2001;21(2A):1173–1179.
20.
AndroulidakiADermitzakiEVenihakiM. Corticotropin releasing factor promotes breast cancer cell motility and invasiveness. Mol Cancer. 2009;8:30.
21.
GrazianiGFerrandinaGPozzoliG. Corticotropin-releasing hormone receptor-1 in human endometrial cancer. Oncol Rep. 2006;15(2):375–379.
22.
ObleDALoeweRYuP. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:3.
23.
RollinsBJ. Release the hounds! A chemokine elicits monocytes from bone marrow. Nat Immunol. 2006;7(3):230–232.
24.
RollinsBJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006;42(6):760–767.
25.
QuesnelB. Tumor dormancy and immunoescape. APMIS. 2008;116(7-8):685–694.
26.
HuangHCHuangCYLin-ShiauSY. Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009;48(6):517–531.
27.
KoontongkaewSAmornphimolthamPYapongB. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells. Cell Biol Int. 2009;33(2):165–173.
28.
RomeroJMSáenz-LópezPCózarJM. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009;70(1):60–64.
29.
FongYCHsuSFWuCL. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer. 2009;64(1):13–21.
30.
SaudemontAJouyNHetuinD. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood. 2005;105(6):2428–2435.
31.
QuesnelB. Tumor dormancy: is adaptative immunity a key player?Med Sci (Paris). 2008;24(6-7):575–576.
32.
ZafiropoulosACrikasNPassamAM. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004;41(5):e59.
33.
Suarez-CuervoCHarrisKWKallmanL. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat. 2003;80(1):71–78.
34.
ZouWMachelonVCoulomb-L’HerminA. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7(12):1339–1346.
35.
UpadhyayRJainMKumarSGhoshalUCMittalB. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol. 2008;128(2):199–204.
36.
HuangHCHuangCYLin-ShiauSYLinJK. Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 gliomo invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009;48(6):517–531.
37.
KoontongkaewSAmornphimolthamPYapongB. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells. Cell Biol Int. 2009;33(2):165–173.
38.
RomeroJMSáenz-LópezPCózarJM. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009;70(1):60–64.
39.
FongYCHsuSFWuCL. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer. 2009;64(1):13–21.
40.
YuanQLiPDLiBH. Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells. J Cancer Res Clin Oncol. 2009;135(1):131–140.
